LP
GYRE icon

LMR Partners’s Gyre Therapeutics GYRE Stock Holding History

LMR Partners’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,704
Closed -$63K – 464
2019
Q3 		$63K Hold
1,704
– – ﹤0.01% 370
2019
Q2 		$94K Buy
+1,704
New +$106K ﹤0.01% 367
2014
Q3 		– Sell
-77
Closed -$272K – 393
2014
Q2 		$272K Buy
+77
New +$251K 0.02% 352

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LMR Partners's GYRE Position: Q4 2019 in Review

LMR Partners sold out of Gyre Therapeutics (GYRE) in Q4 2019, closing a stake of 1,704 shares — an estimated $63K sold.

LMR Partners first reported a position in GYRE in Q2 2014 and held it in 3 quarters. The position peaked at $272K in Q2 2014. 46 funds tracked by Wall St. Rank hold GYRE as of Q4 2019.

  • LMR Partners reported no remaining Gyre Therapeutics position as of Q4 2019 after selling out during the quarter.
  • LMR Partners sold 1,704 Gyre Therapeutics shares in Q4 2019, an estimated $63K.
  • LMR Partners first reported a position in Gyre Therapeutics in Q2 2014 and held it in 3 quarters.
  • LMR Partners's Gyre Therapeutics position peaked at $272K in Q2 2014.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2019.

Based on LMR Partners's 13F filing for Q4 2019, filed 14 Feb 2020.